Hua Medicine Receives Milestone Payment from Bayer for Dorzagliatin
China-based Hua Medicine has announced receiving a RMB 400 million (USD 59 million) milestone payment...
Diabetes
Asia Regenerative Medicine Raises Pre-Series A+ Funding for Bioartificial Organs
Shenzhen-based Asia Regenerative Medicine (ARM) has reportedly raised “tens of millions” of renminbi in a...
Eli Lilly’s Tirzepatide Achieves Primary Endpoints in Chinese Obesity Study
US major Eli Lilly (NYSE: LLY) has announced that the Phase III SURMOUNT-CN study for...
Novo Nordisk Posts Strong 2022 Results; GLP-1 Therapies Drive Growth
Denmark-based diabetes giant Novo Nordisk (NYSE: NVO) has reported financial results for the fourth quarter...
Sciwind Biosciences Initiates Phase III Trial for Ecnoglutide in Type 2 Diabetes
Hangzhou-based Sciwind Biosciences Co., Ltd has announced the first subject dosing in a Phase III...
Haisco’s Prostate Cancer Drug HSK38008 and DPP-4 Inhibitor HSK7653 Accepted for Review
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the clinical trial filing for...
Structure Therapeutics Files for IPO on NASDAQ to Raise $119M
Structure Therapeutics Inc. (Nasdaq: GPCR), a Sino-US firm formerly known as ShouTi Inc., has filed...
Guangzhou’s Overseas Pharma Wins China Clinical Trial Approval for OPL-038
Guangzhou-based Overseas Pharmaceuticals, Ltd has secured clinical trial approval in China for its sustained and...
Sanofi’s iGlarLixi Approved in China for Type 2 Diabetes Management
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that the National Medical Products Administration (NMPA)...
Innovent Biologics Doses First Patient in Phase III Study for Mazdutide
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient has been dosed...
HighTide Therapeutics Completes $107 Million Series C and C+ Financing Rounds
China-based HighTide Therapeutics Inc. has announced the completion of Series C and C+ financing rounds,...
Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline
China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion...
BrightGene Receives NMPA Approval for BGM0504 Clinical Trial
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced that it has received clinical...
PingAn Good Doctor Partners to Establish Lifestyle Medicine
China-based PingAn Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor,...
Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...
Jiangsu Hengrui Gets NMPA Approval for HR20031 Clinical Study in Type 2 Diabetes
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving approval from the National Medical Products...
China Updates Hypertension Guidelines, Lowers Diagnostic Threshold
The National Center for Cardiovascular Diseases, the Chinese Medical Doctor Association (CMDA), and other organizations...
Novo Nordisk Reports 16% YOY Growth in Q3, Raises Full-Year Guidance
Denmark-based biopharma Novo Nordisk A/S (NYSE: NVO) has released its Q3 2022 earnings report. The...
Eccogene Gains FDA Approval for Phase I Study of ECC5004
Shanghai-based Eccogene has announced receiving approval from the US FDA to initiate a Phase I...
Shanghai SMPA Suspends HEC’s Linagliptin Procurement Over Patent Infringement
The Shanghai Sunshine Medical Procurement All-in-One (SMPA) platform has revealed that it has suspended the...